During a recent divisional grand rounds presentation, I asked a room full of my colleagues how many of them had been asked about turmeric by a patient within the past year, month, week or day. Most hands remained up by the end of the exercise. During a recent trip to New York City, I was…
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
Data from the ACR’s Rheumatology Informatics System for Effectiveness (RISE) were used by rheumatology researchers in a crop of new studies that will be presented at the 2018 ACR/ARHP Annual Meeting, Oct. 19–24 in Chicago. Six abstracts, including four oral and two poster presentations, were accepted for this year’s meeting. They explore topics ranging from…
New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…
In a long-term study, apremilast was well tolerated by patients with psoriatic arthritis, who showed sustained improvements for up to five years…
(Reuters)—An experimental osteoarthritis drug developed by Pfizer Inc and Eli Lilly and Co achieved its main goal of lowering pain in a late stage trial, the companies said on Wednesday, potentially offering a safer alternative to opioids. Opioid abuse has reached epidemic proportions in the United States and drugmakers have been looking for less addictive…
BALTIMORE—Rheumatologists may not think about osteoporosis on a daily basis, but they should, said Dr. Karl Insogna, the Ensign Professor of Medicine at Yale University School of Medicine and director of the Yale Bone Center in New Haven, Conn., in his recent lecture at the Maryland Society for the Rheumatic Diseases. With approximately 75 million…
As if the fatigue, joint pain, etc., were not enough, new research has found many lupus patients must contend with clinical depression as well—something that can have a devastating cascade effect on other areas of their lives. Are adults with childhood-onset lupus at greater risk of depression than lupus patients with onset of disease during…
The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…
A recent position statement by the Society of Behavioral Medicine (SBM) concludes that patients with persistent pain need better access to psychosocial care in all healthcare settings.1 The SBM offers 10 health policy recommendations for improving such access, including removing system-related barriers, providing referral tools, reimbursing for evidence-based psychosocial approaches, prioritizing generalist-level and specialist pain…